NuView Life Sciences

What NuView Life Sciences does

NuView Life Sciences is a clinical-stage radiopharmaceutical company developing oncology products that target vasoactive intestinal peptide receptor type 1 (VPAC1), a G-protein-coupled receptor (GPCR) overexpressed on the surface of multiple cancer types. Founded in 2005 and headquartered in Park City, Utah, the company's proprietary platform — NV-VPAC1 — is a small molecule peptide construct that binds to VPAC1 receptors and is paired with Copper-64 (Cu-64) for diagnostic imaging and Copper-67 (Cu-67) for therapeutic applications, marketed under the "Targeted Copper Theranostics (TCT)" framework. The technology was invented by Dr. Mathew Thakur at Thomas Jefferson University and is supported by a portfolio of 20 granted patents held by the inventor.

The product portfolio spans three modalities: an in vitro liquid biopsy kit that detects shed prostate and bladder cancer cells in voided urine using a fluorophore-conjugated NV-VPAC1; an in vivo PET imaging agent (Cu-64-labeled) for breast and prostate cancer localization in soft tissue, bone, and lymph nodes; and a Cu-67-labeled theranostic for targeted radiotherapy. Pipeline indications in clinical trials include prostate, bladder, breast, brain (glioblastoma), and pancreatic cancers. Receptor expression data indicate VPAC1 overexpression in 100% of tested breast carcinoma, prostate carcinoma, meningioma, bladder carcinoma, endometrial carcinoma, and paraganglioma samples.

NuView operates a pre-commercial business model, with revenue dependent on future regulatory approvals and institutional sales to hospital radiology departments, cancer centers, and clinical laboratories. Radiopharmaceutical manufacturing is outsourced to SpectronRx (a contract radiopharmaceutical development and manufacturing organization), removing the need for proprietary cyclotron infrastructure. The company's go-to-market motion centers on clinical validation followed by a sequenced regulatory pathway: initiating clinical trials in Mexico through its NuView LATAM (NV-LATAM) subsidiary (established November 2021), pursuing COFEPRIS approval as the first regulatory milestone, then requesting U.S. FDA reciprocal recognition for American market entry. Distribution is expected to flow through hospital pharmacies and radiopharmacy networks upon commercialization.

Name

NuView Life Sciences

Legal name

NuView Life Sciences, Inc.

Website

https://nuviewlifesciences.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

NuView Life Sciences is a clinical-stage radiopharmaceutical company developing NV-VPAC1, a proprietary VPAC1-targeting platform paired with Copper-64/Copper-67 for cancer diagnostics, liquid biopsy, and theranostics across prostate, bladder, breast, brain, and pancreatic cancers. It targets hospital systems, cancer centers, and clinical laboratories.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals / Cancer Diagnostics & Theranostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)

Keywords

• Cancer diagnostic imaging
• Radiopharmaceutical theranostics
• Liquid biopsy diagnostics
• PET imaging agents
• Targeted cancer therapy

Headquarters

HQ city

Park City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. In Vitro Diagnostic Kits: NuView plans to commercialize its NV-VPAC1 liquid biopsy diagnostic kit for detecting shed cancer cells in biofluids. The kit would be sold to clinical laboratories and hospital systems for use in cancer diagnosis, providing a binary yes/no result.
2. In Vivo PET Imaging Agents: Commercialization of NV-VPAC1 as a PET imaging agent (using Cu-64) for in vivo cancer diagnosis, sold to hospital radiology departments and imaging centers for clinical use in breast, prostate, and other VPAC1-overexpressing cancers.
3. Theranostic Products (Cu-67): Following diagnostic approval, NuView plans to expand into therapeutic applications using Copper-67 labeled NV-VPAC1 for targeted radiotherapy of cancer cells, generating revenue from hospital-based radiopharmacy dispensing.
4. Lateral Flow Strip Test: In vitro application also under development for use as a lateral flow strip pad test, enabling point-of-care cancer screening outside laboratory settings.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

NuView Life Sciences is a clinical-stage radiopharmaceutical company developing next-generation oncology products using its proprietary NV-VPAC1 platform. The platform pairs Copper-64 (Cu-64) for diagnostics with Copper-67 (Cu-67) for therapy, enabling in vitro liquid biopsy diagnostic kits that detect shed cancer cells in biofluids, in vivo PET imaging agents for cancer localization, and theranostic products for targeted radiotherapy of cancer cells overexpressing VPAC1 receptors.

Product overview

NuView Life Sciences is a clinical-stage radiopharmaceutical company developing next-generation oncology products based on its proprietary NV-VPAC1™ platform technology. The platform employs "pairing" of Copper-64 (Cu-64) for diagnostics and Copper-67 (Cu-67) for therapy, enabling targeted copper theranostics (TCT). The product portfolio includes in vitro diagnostic kits that detect shed cancer cells in voided urine (liquid biopsy), in vivo PET imaging agents for diagnosing breast and prostate cancer, and theranostics applications for targeted cancer treatment. The NV-VPAC1 technology targets VPAC1 receptors overexpressed on various cancer cells including prostate, bladder, breast, brain, lung, cervical, and colon cancers.

Differentiator

Problem solved

Functional benefit

Brands

• NV-VPAC1: Proprietary small molecule peptide construct targeting VPAC1 receptors for cancer diagnosis and theranostics applications, including in vitro diagnostics and in vivo PET imaging.
• NV-LATAM
• Targeted Copper Theranostics (TCT)
• NV-VPAC1 Lab Assays

Products and services

• NV-VPAC1 In Vitro Diagnostic Kit An in vitro diagnostic kit using NV-VPAC1 paired with a fluorophore to detect shed prostate and bladder cancer cells in voided urine (liquid biopsy), providing a binary yes/no result without invasive surgical biopsy. Designed for use by clinical laboratories and hospital systems performing cancer diagnostic testing on biofluid samples.
• NV-VPAC1 In Vivo PET Imaging Agent A Positron Emission Tomography (PET/PET-CT/PET-MRI) imaging agent utilizing Copper-64 (Cu-64) positron emitter labeled to NV-VPAC1 for the in vivo diagnosis of breast and prostate cancer by localizing VPAC1-overexpressing cancer cells in soft tissue, bone, and lymph nodes. Designed for use by hospital radiology departments and cancer imaging centers.
• NV-VPAC1 Targeted Copper Theranostics (Cu-67 Therapy) A therapeutic radiopharmaceutical pairing Copper-67 (Cu-67) labeled NV-VPAC1 for targeted radiotherapy of cancer cells overexpressing VPAC1 receptors, enabling personalized treatment planning through pre-therapy diagnostic imaging. Designed for hospital-based radiopharmacy dispensing and oncology treatment centers following regulatory approval.

Quantifiable outcome

• VPAC1 receptor overexpression confirmed in 100% of breast carcinoma (68/68), prostate carcinoma (37/37), meningioma (27/27), bladder carcinoma (4/4), endometrial carcinoma (12/12), and paraganglioma (18/18) samples tested.
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• SpectronRxcoreStrategic or Co-development Partner · 1 January 2020SpectronRx is a Contract Radiopharmaceutical Development and Manufacturing Organization (cRDMO) providing clinical and commercial-scale radiolabeling and manufacturing services. NuView is listed among SpectronRx's client roster alongside Y-mAbs and Telix Pharmaceuticals. SpectronRx specializes in early-stage development, clinical trial supply, commercial supply, and specialty services for radiopharmaceuticals. The partnership enables NuView to scale its radiopharmaceutical manufacturing without building proprietary infrastructure.
• Thomas Jefferson UniversitycoreStrategic or Co-development PartnerThomas Jefferson University in Philadelphia is where Dr. Mathew Thakur (Director of Radiopharmaceutical Research and Molecular Imaging) invented the NV-VPAC1 technology. The university serves as NuView's primary research and clinical collaboration partner, having also developed liquid biopsy diagnostic applications with Dr. Leonard Gomella. The technology was invented at Thomas Jefferson University and later licensed to NuView Life Sciences for commercialization.
• Dr. Leonard Gomella (Thomas Jefferson University)coreStrategic or Co-development PartnerDr. Leonard Gomella collaborated with Dr. Mathew Thakur at Thomas Jefferson University to apply NV-VPAC1 technology to liquid biopsy diagnostic applications. This co-development work expanded the platform from in vivo imaging to non-invasive in vitro diagnostics using biofluids, significantly broadening the commercial applications of the technology.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Curium Pharma: Global radiopharmaceutical manufacturer and distributor of diagnostic and therapeutic nuclear medicine products. Overlaps with NuView's PET imaging and theranostic commercial channels.
• GE HealthCare: Broad medical imaging incumbent including PET/CT scanners, radiopharmacy operations (cyclotrons), and emerging theranostic offerings. Board member A.J. Boechler previously led GE Healthcare's PET/radiopharmacy launches.
• Novartis: Global pharmaceutical leader with Pluvicto (Lu-177 PSMA-617) and Lutathera (Lu-177 dotatate) radioligand therapies that define the commercial theranostics standard. Competes with NV-VPAC1 in prostate and neuroendocrine tumors with vastly greater scale and commercial infrastructure.
• Bracco Imaging: Global diagnostic imaging agent company with broad contrast media and nuclear medicine portfolio. Overlaps with NuView's in vivo PET imaging agent positioning in the hospital radiology channel.
• Bayer: Diversified pharmaceutical incumbent with Xofigo (Ra-223 dichloride) and broader radiopharmaceutical portfolio. Represents a broad incumbent competing for hospital accounts and nuclear medicine infrastructure.
• Cardinal Health (Nuclear & Precision Health Solutions): Operates one of the largest U.S. radiopharmacy networks distributing PET imaging agents and therapeutic radiopharmaceuticals. Functions as a both competitor (distribution) and channel partner (Jill Helmke previously worked there in nuclear medicine).

Emerging players

• Y-mAbs Therapeutics: Clinical-stage oncology company commercializing targeted radiopharmaceuticals (e.g., DANYELZA) and listed alongside NuView on SpectronRx's client roster. Comparable clinical-stage scale and similar outsourced-manufacturing model.

Direct peers

• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing PSMA-targeted imaging (Illuccix) and therapeutic agents for prostate and other cancers. Direct competitor to NuView's NV-VPAC1 PSMA-targeted platform and a co-client of manufacturing partner SpectronRx.
• Lantheus Holdings: Diagnostic imaging company commercializing Pylarify (F-18 piflufolastat) for PSMA PET imaging in prostate cancer. Direct competitor to NuView's NV-VPAC1 in vivo PET imaging agent for prostate cancer.
• POINT Biopharma: Clinical-to-commercial radiopharmaceutical company developing PNT2002 (Lu-177 PSMA) and PNT2003 (Lu-177 dotatate) before being acquired by Eli Lilly. Highly comparable development-stage PSMA/theranostics peer.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NuView Life Sciences